Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives.
Songfeng ZhaoYuhong ChengXin TongMingyang HanLinjin JiYuxiong CheWeiwu HuAihua LiuPublished in: BMJ open (2022)
MRI-guided intravenous r-tPA for patients with AIS with an unknown time of onset is cost-effective in China and cost-saving in the USA.